These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34873470)

  • 1. CD11b
    Kudo-Saito C; Ogiwara Y; Imazeki H; Boku N; Uemura Y; Zhang R; Kawano-Nagatsuma A; Kojima M; Ochiai A
    Am J Cancer Res; 2021; 11(11):5428-5439. PubMed ID: 34873470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD11b
    Imazeki H; Ogiwara Y; Kawamura M; Boku N; Kudo-Saito C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34261702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity.
    Kudo-Saito C; Ishida A; Shouya Y; Teramoto K; Igarashi T; Kon R; Saito K; Awada C; Ogiwara Y; Toyoura M
    Cell Rep; 2018 Aug; 24(7):1790-1801. PubMed ID: 30110636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the FSTL1-DIP2A axis in early-stage tongue cancer.
    Kudo-Saito C; Matsumura S; Mori T; Honma Y; Yoshimoto S
    Am J Cancer Res; 2024; 14(8):3816-3825. PubMed ID: 39267678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.
    Ogiwara Y; Nakagawa M; Nakatani F; Uemura Y; Zhang R; Kudo-Saito C
    Cancer Lett; 2022 Jul; 537():215690. PubMed ID: 35439537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
    Zhou G; Noordam L; Sprengers D; Doukas M; Boor PPC; van Beek AA; Erkens R; Mancham S; Grünhagen D; Menon AG; Lange JF; Burger PJWA; Brandt A; Galjart B; Verhoef C; Kwekkeboom J; Bruno MJ
    Oncoimmunology; 2018; 7(7):e1448332. PubMed ID: 29900067
    [No Abstract]   [Full Text] [Related]  

  • 7. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.
    Nie E; Miao F; Jin X; Wu W; Zhou X; Zeng A; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Liu N; You Y
    Oncogene; 2019 Apr; 38(15):2706-2721. PubMed ID: 30542120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic resistance exercise increases skeletal muscle-derived FSTL1 inducing cardiac angiogenesis via DIP2A-Smad2/3 in rats following myocardial infarction.
    Xi Y; Hao M; Liang Q; Li Y; Gong DW; Tian Z
    J Sport Health Sci; 2021 Sep; 10(5):594-603. PubMed ID: 33246164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follistatin-like 1 attenuates apoptosis via disco-interacting protein 2 homolog A/Akt pathway after middle cerebral artery occlusion in rats.
    Liang X; Hu Q; Li B; McBride D; Bian H; Spagnoli P; Chen D; Tang J; Zhang JH
    Stroke; 2014 Oct; 45(10):3048-3054. PubMed ID: 25139876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of follistatin-like protein 1 expression in colorectal cancer and its association with clinical outcomes.
    Zhao Y; Ou Q; Deng Y; Peng J; Li C; Li J; Zhao Q; Qiu M; Wan D; Fang Y; Pan Z
    Ann Transl Med; 2019 Nov; 7(21):606. PubMed ID: 32047767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DIP2A functions as a FSTL1 receptor.
    Ouchi N; Asaumi Y; Ohashi K; Higuchi A; Sono-Romanelli S; Oshima Y; Walsh K
    J Biol Chem; 2010 Mar; 285(10):7127-34. PubMed ID: 20054002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway.
    Gu C; Wang X; Long T; Wang X; Zhong Y; Ma Y; Hu Z; Li Z
    Cell Death Dis; 2018 May; 9(6):654. PubMed ID: 29844309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer.
    Ozawa H; Imazeki H; Ogiwara Y; Kawakubo H; Fukuda K; Kitagawa Y; Kudo-Saito C
    Transl Oncol; 2022 Feb; 16():101307. PubMed ID: 34902741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follistatin-like protein 1 sustains colon cancer cell growth and survival.
    Bevivino G; Sedda S; Franzè E; Stolfi C; Di Grazia A; Dinallo V; Caprioli F; Facciotti F; Colantoni A; Ortenzi A; Rossi P; Monteleone G
    Oncotarget; 2018 Jul; 9(58):31278-31290. PubMed ID: 30131854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragalus polysaccharide ameliorates CD8
    Li Q; Zhang C; Xu G; Shang X; Nan X; Li Y; Liu J; Hong Y; Wang Q; Peng G
    Biomed Pharmacother; 2024 Feb; 171():116172. PubMed ID: 38278025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follistatin-like 1 is a myokine regulating lipid mobilization during endurance exercise and recovery.
    Nam JS; Park SJ; Ahn CW; Cho ES; Kim HJ; Kim Y
    Obesity (Silver Spring); 2024 Feb; 32(2):352-362. PubMed ID: 38018497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.
    Oshima K; Shoji H; Boku N; Hirano H; Okita N; Takashima A; Kato K; Kudo-Saito C
    Am J Cancer Res; 2024; 14(3):1174-1189. PubMed ID: 38590413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction.
    Kudo-Saito C; Fuwa T; Murakami K; Kawakami Y
    Cancer Res; 2013 Oct; 73(20):6185-93. PubMed ID: 23966294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL25
    Ozaki Y; Kinowaki K; Kawabata H; Kudo-Saito C
    Am J Cancer Res; 2023; 13(10):4931-4943. PubMed ID: 37970362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.